Real-World Study on Nano-Crystalline Megestrol Acetate for Cachexia in TKI-Treated Advanced Digestive Tumors
This study is a prospective, observational clinical study aimed at evaluating the efficacy of Megestrol Acetate for cachexia in patients with advanced digestive system tumors receiving TKI-based therapy.
Cachexia|Digestive System Cancer|Gastric Cancer|Colorectal Cancer|Hepatocellular Carcinoma
DRUG: Nano-crystalline Megestrol Acetate Oral Suspension|DRUG: TKI-Based Therapy
Appetite improvement level, Proportion of subjects with an improvement in appetite based on A/CS-12 after 12 weeks of treatment, From baseline to Week 12 (end of treatment period)|Weight improvement level, Proportion of subjects who did not lose weight relative to baseline after 12 weeks of treatment, From baseline to Week 12 (end of treatment period)
progression-free survival (PFS), defined as the duration from the start treatment to progression, or patient death, From the date of randomization until the first documented disease progression or death from any cause, whichever occurs firstï¼Œassessed up to 24 months
This study is a prospective, observational clinical study aimed at evaluating the efficacy of Megestrol Acetate for cachexia in patients with advanced digestive system tumors receiving TKI-based therapy.